143 related articles for article (PubMed ID: 17699773)
1. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized.
Padrón D; Sato M; Shay JW; Gazdar AF; Minna JD; Roth MG
Cancer Res; 2007 Aug; 67(16):7695-702. PubMed ID: 17699773
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
3. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.
Hosaka T; Inoue F; Ando K; Ishida H; Kusumoto S; Sugiyama T; Shirai T; Okuda K; Hirose T; Ohnishi T; Horichi N; Saijo N; Adachi M; Nakadate T; Kuroki T; Ohmori T
Anticancer Res; 2007; 27(4B):2253-63. PubMed ID: 17695511
[TBL] [Abstract][Full Text] [Related]
4. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.
Yang S; Qu S; Perez-Tores M; Sawai A; Rosen N; Solit DB; Arteaga CL
Cancer Res; 2006 Jul; 66(14):6990-7. PubMed ID: 16849543
[TBL] [Abstract][Full Text] [Related]
5. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.
Shtiegman K; Kochupurakkal BS; Zwang Y; Pines G; Starr A; Vexler A; Citri A; Katz M; Lavi S; Ben-Basat Y; Benjamin S; Corso S; Gan J; Yosef RB; Giordano S; Yarden Y
Oncogene; 2007 Oct; 26(49):6968-78. PubMed ID: 17486068
[TBL] [Abstract][Full Text] [Related]
6. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor.
Timpson P; Lynch DK; Schramek D; Walker F; Daly RJ
Cancer Res; 2005 Apr; 65(8):3273-80. PubMed ID: 15833860
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma.
Das AK; Chen BP; Story MD; Sato M; Minna JD; Chen DJ; Nirodi CS
Cancer Res; 2007 Jun; 67(11):5267-74. PubMed ID: 17545606
[TBL] [Abstract][Full Text] [Related]
8. The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination.
Visser GD; Lill NL
Exp Cell Res; 2005 Dec; 311(2):281-93. PubMed ID: 16246327
[TBL] [Abstract][Full Text] [Related]
9. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Das AK; Sato M; Story MD; Peyton M; Graves R; Redpath S; Girard L; Gazdar AF; Shay JW; Minna JD; Nirodi CS
Cancer Res; 2006 Oct; 66(19):9601-8. PubMed ID: 17018617
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
11. [Ubiquitination-mediated degradation of epidermal growth factor receptor].
Xiu X; Lü ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):120-7. PubMed ID: 15782507
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.
Furukawa M; Nagatomo I; Kumagai T; Yamadori T; Takahashi R; Yoshimura M; Yoneda T; Takeda Y; Goya S; Matsuoka H; Kijima T; Yoshida M; Osaki T; Tachibana I; Greene MI; Kawase I
DNA Cell Biol; 2007 Mar; 26(3):178-85. PubMed ID: 17417946
[TBL] [Abstract][Full Text] [Related]
13. The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of the epidermal growth factor receptor.
Smith CJ; Berry DM; McGlade CJ
J Cell Sci; 2013 Mar; 126(Pt 6):1366-80. PubMed ID: 23418353
[TBL] [Abstract][Full Text] [Related]
14. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
16. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation.
Grøvdal LM; Stang E; Sorkin A; Madshus IH
Exp Cell Res; 2004 Nov; 300(2):388-95. PubMed ID: 15475003
[TBL] [Abstract][Full Text] [Related]
17. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes.
Grandal MV; Zandi R; Pedersen MW; Willumsen BM; van Deurs B; Poulsen HS
Carcinogenesis; 2007 Jul; 28(7):1408-17. PubMed ID: 17372273
[TBL] [Abstract][Full Text] [Related]
18. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
20. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor.
Oksvold MP; Thien CB; Widerberg J; Chantry A; Huitfeldt HS; Langdon WY
Oncogene; 2003 Nov; 22(52):8509-18. PubMed ID: 14627991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
